Richard E Chaisson Selected Research

Rifamycins

1/2020	High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
10/2015	Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
11/2008	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
10/2003	Treatment of chronic infections with rifamycins: is resistance likely to follow?

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard E Chaisson Research Topics

Disease

80	Tuberculosis (Tuberculoses) 09/2022 - 04/2002
22	HIV Infections (HIV Infection) 10/2021 - 04/2003
15	Infections 01/2021 - 01/2002
11	Acquired Immunodeficiency Syndrome (AIDS) 01/2021 - 07/2002
10	Latent Tuberculosis 01/2019 - 07/2002
6	Pulmonary Tuberculosis 01/2021 - 08/2006
6	Coinfection 01/2015 - 08/2003
5	Disease Progression 11/2019 - 03/2003
5	Drug-Related Side Effects and Adverse Reactions 01/2016 - 03/2003
4	Hepatitis B 01/2014 - 11/2004
3	Multiple Organ Failure (MODS) 10/2007 - 12/2002
2	COVID-19 01/2022 - 01/2021
2	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 01/2020 - 01/2018
2	Communicable Diseases (Infectious Diseases) 10/2016 - 10/2016
2	Liver Diseases (Liver Disease) 01/2015 - 01/2005
2	Tuberculous Pericarditis 12/2014 - 09/2014
2	Immune Reconstitution Inflammatory Syndrome 01/2012 - 04/2011
2	Anemia 11/2011 - 01/2008
2	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 05/2011 - 10/2007
2	Nausea 01/2008 - 08/2006
2	Hepatitis C 01/2005 - 01/2002
2	Hepatitis 11/2004 - 01/2002
1	Hypertension (High Blood Pressure) 01/2020
1	Infant Death 01/2018
1	Latent Infection 01/2018
1	Rheumatoid Arthritis 07/2012
1	Psoriatic Arthritis 07/2012
1	Ankylosing Spondylitis 07/2012
1	Reinfection 06/2011
1	Silicotuberculosis 05/2011
1	Malaria 07/2010
1	Overweight 06/2010
1	Viremia 12/2009
1	Chronic Hepatitis B 12/2008
1	Hypersensitivity (Allergy) 11/2008
1	Vomiting 01/2008
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2008
1	Dizziness (Lightheadedness) 01/2008
1	Neutropenia 01/2008
1	Exanthema (Rash) 01/2008
1	Bacterial Pneumonia 10/2007
1	Bacterial Infections (Bacterial Infection) 10/2007
1	Pneumonia (Pneumonitis) 10/2007
1	Salmonella Infections (Salmonellosis) 10/2007
1	Silicosis 06/2005

Drug/Important Bio-Agent (IBA)

38	Isoniazid (Ftivazide)FDA LinkGeneric 12/2021 - 12/2002
25	Pharmaceutical PreparationsIBA 09/2022 - 03/2002
19	rifapentine (Priftin)FDA Link 09/2022 - 04/2006
15	Rifampin (Rifampicin)FDA LinkGeneric 01/2021 - 07/2002
11	Tuberculin (PPD)IBA 12/2021 - 06/2002
10	Moxifloxacin (Avelox)FDA Link 09/2022 - 02/2004
9	Pyrazinamide FDA LinkGeneric 01/2021 - 07/2002
7	efavirenz (Sustiva)FDA Link 09/2022 - 01/2002
7	RNA (Ribonucleic Acid)IBA 11/2011 - 03/2002
5	Ethambutol (Myambutol)FDA LinkGeneric 01/2021 - 08/2006
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2016
4	RifamycinsIBA 01/2020 - 10/2003
4	GoldIBA 01/2014 - 09/2003
3	9 alpha,11 alpha,15 alpha- trihydroxy- 16- phenoxy- 17,18,19,20- tetranorprosta- 4,5,13- trienoic acid (TPT)IBA 02/2021 - 10/2020
3	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 01/2014 - 07/2010
3	lipoarabinomannan (LAM)IBA 10/2011 - 10/2009
3	EnzymesIBA 10/2011 - 11/2004
3	Protease Inhibitors (Protease Inhibitor)IBA 11/2004 - 01/2002
3	Heroin (Diamorphine)IBA 05/2004 - 03/2002
2	VaccinesIBA 01/2022 - 11/2019
2	Dihydrotachysterol (AT 10)IBA 01/2022 - 05/2011
2	Clofazimine (Lamprene)FDA Link 01/2019 - 01/2018
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2014 - 06/2007
2	DNA (Deoxyribonucleic Acid)IBA 01/2014 - 10/2007
2	AntibodiesIBA 01/2014 - 06/2002
2	Reverse Transcriptase InhibitorsIBA 12/2009 - 08/2003
2	insulin receptor-related receptor (IRR)IBA 03/2009 - 06/2005
2	Nevirapine (Viramune)FDA Link 10/2008 - 01/2002
1	C-Reactive ProteinIBA 01/2022
1	ChAdOx1 nCoV-19IBA 01/2022
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021
1	CreatinineIBA 01/2020
1	dolutegravirIBA 01/2020
1	FluoroquinolonesIBA 02/2016
1	Antitubercular AgentsIBA 01/2016
1	Surface Antigens (Surface Antigen)IBA 01/2014
1	Immunoglobulins (Immunoglobulin)IBA 01/2014
1	Antiviral Agents (Antivirals)IBA 01/2014
1	InterferonsIBA 07/2012
1	golimumab FDA Link 07/2012
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2012
1	AcidsIBA 10/2011
1	ImmunosorbentsIBA 10/2011
1	Anti-Retroviral Agents (Antiretroviral Agents)IBA 04/2011
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 07/2010
1	NucleosidesIBA 12/2009
1	Anti-Bacterial Agents (Antibiotics)IBA 10/2007
1	Illicit Drugs (Recreational Drugs)IBA 03/2006

Therapy/Procedure

57	Therapeutics 12/2021 - 01/2002
19	Highly Active Antiretroviral Therapy (HAART) 09/2014 - 04/2002
9	Art Therapy 01/2018 - 11/2004
3	Duration of Therapy 01/2020 - 02/2004
3	Drug Therapy (Chemotherapy) 01/2016 - 06/2003
2	Immunotherapy 12/2014 - 09/2014
1	Ambulatory Care (Outpatient Care) 11/2008